LACTOLOGY FOUNDATION

Drug class and composition

Hydrotalcite (also known as hydrotalcid) is a crystalline layered double hydroxide containing magnesium and aluminium, used orally as a non‑systemic antacid for dyspepsia and gastro‑oesophageal reflux. It is usually formulated together with hydrated magnesium oxide and mixtures of aluminium carbonate and aluminium hydroxide (e.g. Talcid) to provide acid‑neutralising capacity and mucosal protective effects.

Hydrotalcite acts locally in the gastric lumen, neutralising hydrochloric acid and binding bile acids and pepsin, with minimal systemic absorption of the parent compound. Aluminium and magnesium ions released in the gastrointestinal tract may be partly absorbed but are largely excreted via the kidneys in individuals with normal renal function.

General toxicity

Experimental data indicate low acute toxicity of hydrotalcite and related aluminium–magnesium antacids, with very high oral LD50 values in animals and absence of significant systemic effects at therapeutic doses. Safety data sheets describe no evidence of mutagenicity, carcinogenicity or specific target‑organ toxicity for hydrotalcite itself, although information is incomplete.

Chronic toxicity is mainly linked to aluminium load and to theoretical concerns about modulation of growth factor pathways in the gastric mucosa rather than direct cytotoxicity of hydrotalcite. In patients with severe renal impairment, accumulation of aluminium and magnesium from long‑term, high‑dose antacid use may increase the risk of osteomalacia, encephalopathy or hypermagnesaemia, so prolonged treatment should be avoided or closely monitored in this population.

Reproductive toxicity and pregnancy

Hydrotalcite‑containing antacids are commonly used during pregnancy, but controlled human data are limited. Based on older FDA criteria, hydrotalcite has been classified in pregnancy category C, reflecting either adverse findings in animals or lack of adequate studies in humans, so use should be reserved for clear indications and the lowest effective dose.

No specific teratogenic or mutagenic effects have been demonstrated for hydrotalcite or its aluminium–magnesium components in humans, and extensive clinical experience with antacids of this type has not revealed a characteristic pattern of malformations. Nevertheless, prolonged or excessive dosing during pregnancy is discouraged, and non‑pharmacological measures or alternative agents with a stronger evidence base may be preferred when feasible.

Excretion into breast milk

Aluminium and magnesium salts used as antacids exhibit minimal transfer into breast milk, and the amounts ingested by the nursing infant are very small. Available lactation resources consider aluminium hydroxide and magnesium hydroxide compatible with breastfeeding at usual doses, with only trace aluminium detectable in milk and no reported adverse effects in term infants.

For hydrotalcite specifically, there are no quantitative pharmacokinetic studies in lactating women, but, by analogy with its components and its poor oral bioavailability, clinically relevant exposure of the breastfed infant is unlikely under standard dosing. Chronic, high‑dose maternal use could theoretically increase infant aluminium intake, so prolonged therapy should be avoided, especially in premature or low‑birth‑weight infants who may have increased gastrointestinal absorption.

Lactation risk assessment

General principles of drug transfer into human milk indicate that hydrotalcite, as a non‑lipophilic, poorly absorbed compound with low systemic levels, has a low propensity to concentrate in milk. In term, healthy infants, short‑term maternal use of aluminium–magnesium antacids is considered compatible with breastfeeding by several expert sources, provided doses remain within recommended limits and chronic exposure is avoided.

The local lactation classification used on your site currently assigns hydrotalcite to a category indicating it is relatively unsuitable for use during breastfeeding and that nursing should be interrupted until the drug is eliminated from maternal plasma. This internal categorisation is intentionally conservative because it incorporates not only the low direct milk transfer but also the cumulative aluminium burden and evolving evidence regarding long‑term neurodevelopmental effects, and therefore recommends avoiding routine use during lactation when safer or better‑studied alternatives are available.

Paediatric considerations

The manufacturer advises against routine use of hydrotalcite in paediatric patients below 12 years of age due to insufficient data on efficacy and safety, rather than proven harm. In neonates and premature infants, oral aluminium and magnesium absorption can be higher due to increased intestinal permeability and immature renal clearance, so exposure via breast milk, although low, should be kept as small and as short as possible.

In breastfed infants of mothers taking hydrotalcite, monitoring for gastrointestinal symptoms such as constipation, diarrhoea or vomiting is prudent, especially with prolonged maternal therapy or when other aluminium‑containing products are used concurrently. In the presence of renal dysfunction or other risk factors in the infant, alternative maternal therapies with minimal aluminium content should be preferred.

Clinical recommendations

In pregnancy, hydrotalcite may be considered when non‑pharmacological measures fail and symptoms significantly impair quality of life, but treatment should be time‑limited and based on an individual benefit–risk assessment consistent with its category C status. During lactation, occasional, short‑term maternal use at standard doses is unlikely to pose significant risk to a healthy term infant, yet routine or long‑term use is discouraged in your framework because of aluminium exposure concerns and the availability of alternative strategies for dyspepsia.

Breastfeeding mothers requiring antacid therapy should be counselled about dose limitation, avoidance of chronic self‑medication and the importance of infant monitoring, while clinicians remain alert to emerging evidence that may refine hydrotalcite’s lactation risk profile over time. When feasible, preference may be given to drugs with robust lactation safety data and lower aluminium content, especially in high‑risk dyads such as premature infants or those with renal impairment.